Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Primetime?

Organ preservation for gastroesophageal junction (GEJ) and gastric cancers is emerging as an attainable-but still selective-therapeutic goal. The convergence of effective systemic therapy, enhanced imaging, and endoscopic sophistication has reframed the role of surgery from default to discretionary. Building on watch-and-wait experience from the rectal cancer paradigm (Organ Preservation for Rectal Adenocarcinoma trial and International Watch-and-Wait Database), readiness requires more than feasibility; it depends on biologic predictability, clinical reproducibility, and system capacity. This review synthesizes current evidence on when and for whom nonoperative management may achieve oncologic parity with resection. We examine biologic readiness, defined by tumor subsets such as microsatellite instability-high (MSI-H) and Epstein-Barr virus (EBV)-positive cancers that display immune-mediated clearance after therapy; clinical readiness, reflected in trial data and surveillance protocols that safeguard against undertreatment; and system readiness, encompassing diagnostic infrastructure, workforce expertise, and equitable access to high-quality response evaluation. In esophageal/GEJ disease, Surgery As Needed for Oesophageal cancer trial demonstrates that patients achieving a clinical complete response after chemoradiation can be managed with active surveillance and achieve survival noninferior to immediate surgery, with better early quality of life, provided programs use validated clinical response evaluation, protocolized surveillance, and rapid salvage capacity. For gastric cancer, organ preservation remains investigational outside biomarker-selected contexts (eg, MSI-H, EBV-positive). Implementation demands multidisciplinary infrastructure including validated response assessment, intensive surveillance protocols, and equitable access to biomarker testing and salvage surgery. Without these elements, organ preservation risks widening existing disparities. Across these domains, the evidence suggests a threshold of cautious readiness for GEJ primaries and emerging readiness for gastric cancer. The key challenge is not technical innovation but translation-ensuring that the ability to preserve the organ does not outpace the ability to preserve outcomes. Progress toward that equilibrium will determine whether organ preservation becomes a universal standard or remains an institutional privilege.